Antag Therapeutics CEO Alexander Sparre-Ulrich (L) and Versant's Alex Mayweg
December 4, 2024 03:00 AM EST
Financing
Startups

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

Kyle LaHucik

Senior Reporter

Ver­sant is out with its third obe­si­ty biotech of the year, lead­ing an €80 mil­lion Se­ries A for An­tag Ther­a­peu­tics, a Dan­ish com­pa­ny de­vel­op­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times